BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sigvotatug Vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sigvotatug Vedotin\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04389632-2267@assetmemo.bio
DTSTAMP:20261121T010143Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Sigvotatug Vedotin: Phase 1 readout est. (NCT04389632)
DESCRIPTION:Sigvotatug Vedotin\, phase 1\, Non-Small Cell Lung Cancer.\nStu
 dy: A Study of Sigvotatug Vedotin in Advanced Solid Tumors\nEstimated prim
 ary completion: 16 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sigvotatug-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04389632
URL:https://assetmemo.bio/drug/sigvotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06758401-2267@assetmemo.bio
DTSTAMP:20261121T010143Z
DTSTART;VALUE=DATE:20280905
DTEND;VALUE=DATE:20280906
SUMMARY:Sigvotatug Vedotin: Phase 3 readout est. (NCT06758401)
DESCRIPTION:Sigvotatug Vedotin\, phase 3\, Non-Small Cell Lung Cancer.\nStu
 dy: This is a Study to Learn About How the Combination of the Study Medici
 nes Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small C
 ell Lung Cancer With High Levels of PD-L1.\nEstimated primary completion: 
 5 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sig
 votatug-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06758401
URL:https://assetmemo.bio/drug/sigvotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227298-2267@assetmemo.bio
DTSTAMP:20261121T010143Z
DTSTART;VALUE=DATE:20290308
DTEND;VALUE=DATE:20290309
SUMMARY:Sigvotatug Vedotin: Phase 1/2 readout est. (NCT07227298)
DESCRIPTION:Sigvotatug Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called 
 PF-08634404 in Combination With Different Anticancer Agents in Advanced Ca
 ncers\nEstimated primary completion: 8 March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sigvotatug-vedotin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07227298
URL:https://assetmemo.bio/drug/sigvotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
